Re: Randomized Double-Blind Factorial Trial of Three Treatments to Reduce the Prevalence of Precancerous Gastric Lesions

Abstract

We congratulate You et al. ( 1 ) for the successful completion of their chemoprevention trial. Their results have clear implications for gastric cancer prevention. As emphasized by the authors, all available reports conclude that curing Helicobacter pylori infection is a promising strategy to control gastric cancer. Previously, we supplied the authors with raw data from our Colombian chemoprevention trial at 6 years of follow-up ( 2 , 3 ) . Because our published conclusions, based on the same data, differed considerably from theirs ( 1 ) , we would like to comment on the discrepant interpretations of our results.